

# Mathematical Modeling of the Effects of Mutation on the Immune System

Troy P.T. Teo

umteop@cc.umanitoba.ca


Dept. of Mathematics, University of Manitoba, Canada

Advisors: Julien Arino & Stéphanie Portet

## 1. Introduction

**Goal :** develop a mathematical model to study the interactions b/w immune system, a target population (cancer cells or virus infection) & a mutative target

**Process :**







## 2. Immune System Model Hypotheses

**Populations:**

- Target cells (T):** infected (or tumor) cells surrounded by antigens
- Effector cells (E):** immune system generates cells for fighting cells with specific antigen.
- Mutant cells (M) :** infected cells that have undergone genetic changes (mutations)

**Assumptions:**

- cell population modeling
- E cells - saturated growth, T & M cells -exponential growth
- non specific response of immune system
- different antigenity for target & mutant
  - different stimulation of immune system by target & mutant
  - different immune response on target & mutant
- predator-prey type interactions b/w target-mutant & immune system



## 3. Mathematical Model

**3D ODE Model for target-effector-mutant interactions**

$$\frac{dT}{dt} = r_T T - k_T E T$$


target cells proliferation immune killing

$$\frac{dM}{dt} = r_M M + \gamma T - k_M E M$$

mutant cells proliferation mutation immune killing

$$\frac{dE}{dt} = \frac{\beta E}{\sigma_E + E} - dE + \frac{\rho M E}{\sigma_E + E} + \frac{\alpha T E}{\sigma_E + E}$$

effector cells proliferation death stimulation by mutant M stimulation by target T



$r_T, r_M$  = reproduction rate for target T & mutant M respectively  
 $k_T$  = contact rate between target T & effector E  
 $k_M$  = contact rate between mutant M & effector E  
 $\gamma$  = mutation rate  
 $\beta, d$  = self generation & death rate of effector E respectively  
 $\alpha$  = stimulation of effector E by target / tumor T  
 $\rho$  = stimulation of effector E by mutant M  
 $\sigma$  = critical threshold for cooperative & autocatalytic process

## 4. Mathematical Analysis

**(I) Equilibria**

- $(T_1, M_1, E_1) = (0, 0, 0)$ ;
- $(T_2, M_2, E_2) = (0, 0, \frac{\beta - d\sigma_E}{d})$  (target- & mutant-free equilibrium)
- $(T_3, M_3, E_3) = (0, \frac{(d\sigma_E - \beta)k_M + dr_M}{\rho(\sigma_E k_M + r_M)}, \frac{r_M}{k_M})$  (target-free, mutant endemic)
- $(T_4, M_4, E_4) = (\frac{(k_M E - r_M)M}{\gamma}, \frac{d - \beta}{\rho + \frac{\alpha}{\gamma}(\frac{r_T}{k_T} - r_M)}, \frac{r_T}{k_T})$  (target & mutant endemic)

**(II) Local Stability Analysis of Equilibria**

**Method:**

- linearization of system (Jacobian Matrix)
- study of eigenvalues  $\lambda$  of the Jacobian  $J$  (e.g Routh Hurwitz Criteria)

**Criteria for Locally Asymptotically Stability:**

- If  $\text{Re}(\lambda) < 0$ ; equilibrium is LAS
- If  $\text{Re}(\lambda) > 0$ ; equilibrium is unstable


$$J = \begin{bmatrix} r_T - k_T E & 0 & -k_T T \\ \gamma & r_M - k_T E & -k_M M \\ \alpha E & \rho E & \frac{\beta}{\sigma_E + E} - \frac{\beta E}{(\sigma_E + E)^2} - d + \rho M + \alpha T \end{bmatrix}$$

**(III) Condition of Existence & Stability of Equilibria**

| Equilibrium       | Condition of Existence  | Condition of Stability  |
|-------------------|---|---|
| $(T_1, M_1, E_1)$ | N.A.  | Unstable  |
| $(T_2, M_2, E_2)$ | $\frac{\beta - d\sigma_E}{d} > 0$   | $\frac{\beta - d\sigma_E}{d} > \max\left(\frac{r_T}{k_T}, \frac{r_M}{k_M}\right)$ |
| $(T_3, M_3, E_3)$ | $\frac{\beta - d\sigma_E}{d} < \frac{r_M}{k_M}$                                   | $\frac{r_M}{k_M} > \frac{r_T}{k_T}$   |
| $(T_4, M_4, E_4)$ | $\frac{r_T}{k_T} > \max\left(\frac{r_M}{k_M}, \frac{\beta - d\sigma_E}{d}\right)$ | $k_M \sigma_E + r_M \geq k_T \sigma_E + r_T$                                      |

## 5. Computational Analysis

**(I) Verification of Equilibrium Stability Conditions**




**(II) Effect of Difference b/w Target & Mutant Fitnesses**

Fitness factor of immune E cells:  $\frac{\beta - d\sigma_E}{d}$

Fitness factor of target T cells:  $\frac{r_T}{k_T}$

Fitness factor of mutant M cells:  $\frac{r_M}{k_M}$

|                                     | $\frac{r_T}{k_T}$ | $\frac{r_M}{k_M}$ | $\frac{\beta - d\sigma_E}{d}$ | $\frac{\beta - d\sigma_E}{d} - \frac{r_M}{k_M}$ | $\frac{r_M}{k_M} - \frac{r_T}{k_T}$ | $(k_M \sigma_E + r_M) - (k_T \sigma_E + r_T)$ |
|-------------------------------------|-------------------|-------------------|-------------------------------|---|-------------------------------------|---|
| $\frac{r_M}{k_M} > \frac{r_T}{k_T}$ | 1                 | 4                 | -3                            | -7 (<0)   | 3 (>0)                              | 0.3   |
| $\frac{r_M}{k_M} < \frac{r_T}{k_T}$ | 4                 | 1                 | -3                            | -4 (<0)   | -3 (<0)                             | 0.375   |



## 6. Applications & Biological Implications


**(I) Treatment and Strength of Infection**

To study the effect of treatment and/or different strengths of infection

- Treatment yields a set of parameter values for T, M & E populations
- Model can be used to predict the response of the populations to the treatment

Different strength/stages of infection yields different initial conditions for T & M

- Model can be used to predict the response of the populations




Two trajectories correspond to infections of different strength started with initial conditions  $(T, E) = (T_1, 0.1)$  and  $(T_2, 0.1)$ . Strength of  $T_2 > T_1$ .

- As T increases, E increases correspondingly to combat infection.
- Complete extermination of T & M is impossible. Targets, mutants & effector cells coexist.

Example of diseases with mutation: HIV

**(II) Immune Memory of Effector Cell**


To study the effect of immunological memory (acquired immune or vaccination)



- Vaccination induces a higher initial immune response
- Immune response has less variations when fighting infection
- Correspondingly, fluctuation of infection is better controlled.

**(III) Mutative retrovirus therapy for cancer treatment**

To study the effect of introducing an engineered mutant cell (retrovirus) for treatment (eg. Retrovirus gene therapy to combat cancer cells)



## Future Work

- Validation of model with clinical data